Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting
PITTSBURGH, June 25, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (OTC: LIPO) ('Lipella' or the 'Company'), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today issued a letter from Chief Executive Officer Jonathan Kaufman to stockholders. The letter provides detailed responses to frequently asked questions regarding the Company's recent delisting from the Nasdaq Capital Market, as well as insight into Lipella's clinical programs, financial position, and plans to relist on a national exchange.
In the letter, Dr. Kaufman acknowledged the many inquiries received from stockholders and reaffirmed the Company's commitment to transparency and long-term value creation.
'While we are disappointed with Nasdaq's decision, Lipella's underlying business remains strong. We are advancing meaningful therapies through the clinical program previously outlined, maintaining full SEC compliance, and actively pursuing relisting,' said Dr. Kaufman. 'Our mission, leadership team, and long-term strategy remain unchanged.'
Key highlights from the letter include:
Relisting Plans: The Company is actively evaluating national exchanges that support early-stage innovation and intends to file an initial listing application in the near future.
Operational Continuity: Lipella remains fully operational, with clinical programs advancing according to plan. The delisting has not impacted clinical timelines or research staffing.
Clinical Pipeline Update: The Company's lead candidates—LP-310 for oral lichen planus and LP-10 for hemorrhagic cystitis—continue to show promising clinical progress. Final topline data from the Phase 2a trial of LP-310 is expected in the second half of 2025.
Financial Standing: Lipella remains financially sound, with sufficient capital to support ongoing development programs and prudent fiscal management in place.
Shareholder Engagement: Lipella will continue to communicate through SEC filings, press releases, and investor outreach, including plans to participate in investor conferences and calls.
The full stockholder letter is available in the Company's latest Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission today.
About Lipella Pharmaceuticals Inc.Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating active agents in existing generic drugs and optimizing these reformulations for new applications. Lipella targets diseases with significant unmet needs, where no approved drug therapies currently exist. The company completed its initial public offering in 2022. Learn more at lipella.com and follow us on X and LinkedIn.
Forward-Looking StatementsThis press release includes certain "forward-looking statements." All statements, other than statements of historical fact, included in this press release regarding, among other things, our strategy, including our intention to pursue a relisting of our common stock on a national exchange, future operations, financial position, prospects, clinical trials, regulatory approvals, pipeline and opportunities, sources of growth, successful implementation of our proprietary technology, plans and objectives are forward-looking statements. Forward-looking statements can be identified by words such as "may," "will," "could," "continue," "would," "should," "potential," "target," "goal," "anticipates," "intends," "plans," "seeks," "believes," "estimates," "predicts," "expects," "projects" and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding future events and financial trends that we believe may affect among other things, market and other conditions, our financial condition, results of operations, business strategy, short- and long-term business operations and objectives, and financial needs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you, therefore, against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. There are risks, uncertainties and other factors, both known and unknown, that could cause actual results to differ materially from those in the forward-looking statements which include, but are not limited to, risks related to our product candidates, including LP-310 and LP-10, general capital market risks, including our ability to relist our common stock on a national exchange, regional, national or global political, economic, business, competitive, market and regulatory conditions, and other risks that may be included in the periodic reports and other filings that the Company files from time to time with the U.S. Securities and Exchange Commission. Any forward-looking statement made by us is based upon the reasonable judgment of our management at the time such statement is made and speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. In addition, the information contained in this press release is as of the date hereof, and the Company has no obligation to update such information, including in the event that such information becomes inaccurate. You should not construe the contents of this press release as legal, tax and financial advisors as to legal and related matters concerning the matters described herein.
CONTACT:Jonathan KaufmanChief Executive OfficerLipella Pharmaceuticals Inc.Info@Lipella.com1-412-894-1853
PCG AdvisoryJeff Ramsonjramson@pcgadvisory.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Sizzling Platter Prices Offering of $500 Million Senior Secured Notes to Finance Acquisition by Bain Capital Private Equity
SALT LAKE CITY--(BUSINESS WIRE)--Sizzling Platter, one of the largest U.S. restaurant franchisee platforms, today announced that affiliates of Bain Capital Private Equity have priced $500 million in aggregate principal amount of 9.500% senior secured notes due 2032 (the 'notes'), to fund the acquisition of Sizzling Platter's parent (the 'Company') by Bain Capital Private Equity. The affiliates, BCPE Flavor Debt Merger Sub, LLC ('Merger Sub') and BCPE Flavor Issuer, Inc. (the 'Co-Issuer') intend to use the net proceeds from the notes offering, together with borrowings under new senior secured credit facilities and equity contributions, to fund the acquisition, repay Sizzling Platter's existing indebtedness and pay related fees and expenses, with the remainder to be used for general corporate purposes. This press release does not constitute a notice of repayment of any outstanding indebtedness of Sizzling Platter. The notes will mature on July 1, 2032, unless earlier repurchased or redeemed in accordance with their terms. The notes offering is expected to close on July 2, 2025, subject to customary closing conditions. Upon consummation of the acquisition, the notes will be guaranteed jointly and severally on a senior secured basis by each existing and future wholly owned subsidiary of the Company (other than the Co-Issuer) that guarantees the Company's obligations under the new senior secured credit facilities, subject to certain exclusions. The notes and the related guarantees were offered to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the 'Securities Act'), and to non-U.S. persons in offshore transactions pursuant to Regulation S under the Securities Act. The notes and related guarantees have not been and will not be registered under the Securities Act or any state or other jurisdiction's securities laws. Accordingly, the notes may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements under the Securities Act and any applicable state or other jurisdiction's securities laws. This press release is neither an offer to sell nor a solicitation of an offer to buy any securities and shall not constitute an offer to sell or a solicitation of an offer to buy, or a sale of any securities in any jurisdiction in which such offer, solicitation or sale is unlawful. Forward-Looking Statements This press release contains statements that are forward-looking statements within the meaning of the federal securities laws and are subject to various risks, uncertainties and assumptions. All statements that are not historical in nature, and which may be identified by the use of words such as 'expects,' 'plans,' 'seeks,' 'anticipates,' 'strategy,' 'believes,' 'intends,' 'may,' 'outlook,' 'forecasts,' 'goal,' 'estimates' and other similar expressions or future or conditional verbs such as 'will,' 'should,' 'would' and 'could' and similar expressions (or the negative of such expressions), are forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the proposed merger and the expected closing of the offering. Forward-looking statements are made based on our current expectations and beliefs concerning future events and, therefore, involve a number of assumptions, risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those indicated by such forward-looking statements. The Company undertakes no obligation to update our forward-looking statements to reflect events and circumstances after the date on which the statements were made or to reflect the occurrence of unanticipated events.
Yahoo
2 hours ago
- Yahoo
Eureka Acquisition Corp Announces Revised Contribution to Trust Account and Terms and Conditions in Connection with Proposed Charter Amendment
New York, June 25, 2025 (GLOBE NEWSWIRE) -- Eureka Acquisition Corp (the 'Company') (Nasdaq: EURK), a blank check company, today announced that in connection with its previously announced extraordinary general meeting in lieu of an annual general meeting of shareholders to be held on June 30, 2025, at 9:00 a.m., Eastern Time (the 'Extraordinary General Meeting'), the Company has revised the contribution to its trust account and the terms and conditions in connection with the proposal to amend the Company's current Charter (the 'Charter Amendment Proposal'). The Charter Amendment Proposal provides that the Company has until July 3, 2025 to complete a business combination, and may elect to extend the period to consummate a business combination up to 12 times, each by an additional one-month extension (the 'Monthly Extension'), for a total of up to 12 months to July 3, 2026. In connection with the Charter Amendment Proposal, the revised terms and conditions (the 'Revised Terms'), among the others, include: If the Charter Amendment Proposal is approved, for each Monthly Extension, the amount of $150,000 shall be deposited into the trust account of the Company (the 'Revised Monthly Extension Fee') (as compared to the originally proposed amount as the lesser of (i) $60,000 for all remaining public shares and (ii) $0.03 for each remaining public share); The Company will file the Current Report on Form 8-K to disclose the deposit of each Revised Monthly Extension Fee timely; In the event that the Revised Monthly Extension Fee is not being deposited into the trust account by the 3rd day of each month since July 3, 2025, the Company has a period of thirty (30) days (the 'Cure Period') to pay any applicable past due payment for the Revised Monthly Extension Fee. If the Company fails to make any applicable past due payment during the Cure Period, then the Company shall immediately cease all operations, except for the purpose of winding up, and liquidate and dissolve with the same effect as if the Company failed to complete a business combination within the prescribed timeline; and The Company will not withdraw any amount out of the interest from the trust account to pay its dissolution expenses. The record date for determining the Company shareholders entitled to receive notice of and to vote at the Extraordinary General Meeting remains the close of business on May 23, 2025 (the 'Record Date'). Shareholders as of the Record Date can vote, even if they have subsequently sold their shares. Shareholders who have previously submitted their proxies or otherwise voted and who do not want to change their vote need not to take any action. Shareholders who have not yet done so are encouraged to vote as soon as possible. There is no change to the location, the Record Date, or any of the other proposals to be acted upon at the Extraordinary General Meeting, except as otherwise provided herein. Shareholders who wish to withdraw their previously submitted redemption request may do so prior to the Extraordinary General Meeting by requesting that the Company's transfer agent return such shares by 5:00 p.m. Eastern Time on June 26, 2025. If you have questions regarding the certification of your position or delivery of your shares, please contact: Continental Stock Transfer & Trust Company1 State Street 30th FloorNew York, NY 10004-1561E-mail: spacredemptions@ The Company's shareholders who have questions regarding the Revised Terms, the Extraordinary General Meeting or would like to request documents may contact the Company's proxy solicitor, Advantage Proxy, Inc., at (877) 870-8565, or banks and brokers can call (206) 870-8565, or by email at ksmith@ About Eureka Acquisition Corp Eureka Acquisition Corp is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, incorporated for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Forward-Looking Statements This press release includes 'forward-looking statements' within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Certain of these forward-looking statements can be identified by the use of words such as 'believes,' 'expects,' 'intends,' 'plans,' 'estimates,' 'assumes,' 'may,' 'should,' 'will,' 'seeks,' or other similar expressions. Such statements may include, but are not limited to, statements regarding the date of the Extraordinary General Meeting and the redemption request deadline. These statements are based on current expectations on the date of this press release and involve a number of risks and uncertainties that may cause actual results to differ significantly. The Company does not assume any obligation to update or revise any such forward-looking statements, whether as the result of new developments or otherwise. Readers are cautioned not to put undue reliance on forward-looking statements. Additional Information and Where to Find It On June 3, 2025, the Company filed a definitive proxy statement with the Securities and Exchange Commission (the 'SEC') in connection with its solicitation of proxies for the Extraordinary General Meeting. The Company will amend and supplement the definitive proxy statement to provide information about the Revised Terms and the Extraordinary General Meeting. INVESTORS AND SECURITY HOLDERS OF THE COMPANY ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND OTHER DOCUMENTS THE COMPANY FILES WITH THE SEC CAREFULLY IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE AS THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of the definitive proxy statement (including any amendments or supplements thereto) and other documents filed with the SEC through the web site maintained by the SEC at or by contacting the Company's proxy solicitor. Participants in the Solicitation The Company and its respective directors and officers may be deemed to be participants in the solicitation of proxies from shareholders in connection with the Extraordinary General Meeting. Additional information regarding the identity of these potential participants and their direct or indirect interests, by security holdings or otherwise, is set forth in the definitive proxy statement. You may obtain free copies of these documents using the sources indicated above. Contact Information:Fen ZhangChairman and Chief Executive OfficerEmail: +86 135 0189 0555
Yahoo
2 hours ago
- Yahoo
Why Nektar Therapeutics Stock Was Red-Hot Today
An analyst tracking the stock made a drastic change to his price target. This closely followed good news from the lab for the company. 10 stocks we like better than Nektar Therapeutics › The latest biotech stock to explode in price, Nektar Therapeutics (NASDAQ: NKTR) was quite the outperformer on the stock exchange for the second day in a row. On Wednesday, one day after delivering excellent news from the lab, the company's shares leaped 19% higher on a significant analyst price target change. Well before market open, H.C. Wainwright's Arthur He poured some rocket fuel into his Nektar price target, setting it anew at $120 per share. That's far above his previous level, which was a mere $6.50. In making the change, he left his buy recommendation intact. In what's hardly a surprising development, He's adjustment was due to the positive results in the latest completed clinical trial for Nektar's eczema drug rezpegaldesleukin. The study put the medicine through its paces for the treatment of moderate-to-severe atopic dermatitis (AD), a form of eczema. In the analyst's view, it did well enough to become a top drug in the treatment of the affliction. On Tuesday, the biotech announced, no doubt with immense satisfaction, that rezpegaldesleukin met all of its primary and secondary endpoints in the phase 2b trial. After 16 weeks of treatment with the subcutaneous drug, patients demonstrated a 53% to 61% improvement in symptoms when measured with an eczema index. This compared very favorably to 31% for patients taking a placebo. This easily makes Nektar's drug the success of the week in the biotech world. As pointed out by He, Rezpegaldesleukin clearly has potential to treat the many people who suffer from AD. As such, the progress of the drug -- and its developer -- will be exciting to watch going forward. Before you buy stock in Nektar Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nektar Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $689,813!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $906,556!* Now, it's worth noting Stock Advisor's total average return is 809% — a market-crushing outperformance compared to 175% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Nektar Therapeutics Stock Was Red-Hot Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
